New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
08:36 EDTSVNTSavient, Sobi announce co promotion agreement for Kineret in the U.S.
Sobi and Savient Pharmaceuticals (SVNT) announced that they have entered into an agreement for the co-promotion of Kineret in the U.S. Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis, or RA, and indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs. Kineret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes called Neonatal-Onset Multisystem Inflammatory Disease.
News For SVNT From The Last 14 Days
Check below for free stories on SVNT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SVNT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use